News Releases

Friday, May 27, 2016

University Hospitals to open $30 Million Proton Therapy Center

CLEVELAND –  University Hospitals is hosting a ribbon-cutting ceremony on May 31 for a new $30 million proton therapy center, becoming one of an elite group of cancer centers in the country to offer this revolutionary technology. There are currently only 23 operational proton therapy centers in the nation and the UH site will be the first in Ohio.
 
The new Proton Therapy Center is one of the world’s first “compact” proton therapy centers, featuring a unique single-room system that is significantly smaller and more economical than first-generation proton therapy technology, while delivering the same powerful cancer-fighting radiation therapy.
 
Proton therapy is an advanced type of radiation treatment that uses a proton beam to precisely target a tumor. Traditional radiation therapy uses photon beams or X-rays, which are highly effective for a broad variety of cancers. However, in some cases, proton beams offer enhanced abilities to deliver radiation doses to destroy cancer cells while selectively sparing surrounding healthy tissue. Most notably, the use of protons is beneficial for the treatment of some cancers in children and young adults, who are more prone to short and long-term complications from radiation.
 


Thursday, May 19, 2016

Robyn H. Strosaker, MD, named VP & Chief Medical Officer at University Hospitals Case Medical Center

CLEVELAND – University Hospitals has announced the appointment of Robyn H. Strosaker, MD, as Vice President and Chief Medical Officer (CMO) at UH Case Medical Center. Her appointment will become effective June 1.
 
The announcement was made by Daniel I. Simon, MD, President of UH Case Medical Center, and Michael R. Anderson, MD, who has held the dual positions of CMO for UH Case Medical Center and the UH system.  Dr. Anderson will remain in the system CMO position.
 
As the CMO of UH Case Medical Center, Dr. Strosaker will lead major initiatives including high-reliability medicine, quality and safety, patient advocacy, physician relations, and utilization and case management for the academic medical center. 


Tuesday, May 17, 2016

University Hospitals to name Cleveland’s large scale BikeShare: UHBikes

CLEVELAND — University Hospitals has entered a new partnership with the city’s much anticipated BikeShare program, including the right to name the system UHBikes. The BikeShare program is a collaboration between UH and Cuyahoga County’s Department of Sustainability, the City of Cleveland, Bike Cleveland, University Circle, Inc., and vendor CycleHop-SoBi, and is scheduled to launch midsummer 2016.

“Our community’s health and well-being is a key priority for UH,” said Thomas F. Zenty III, Chief Executive Officer, University Hospitals. “This sponsorship was an important decision for us because the program accomplishes so much for Greater Cleveland—encouraging physical activity and environmental sustainability, while also creating a new way for visitors to see and discover the city that we know and love.”

“This program is the direct result of a successful public-private partnership. Cuyahoga County is thrilled to see it come to fruition, especially with support and engagement from organizations across the Greater Cleveland area,” said Mike Foley, Director of Sustainability, Cuyahoga County. “We are grateful to all of our partners, especially University Hospitals, for helping to make this a reality.”


Monday, May 02, 2016

UH Seidman Cancer Center first in the world to apply SBRT to partial prostate gland for prostate cancer

CLEVELAND– University Hospitals Seidman Cancer Center physicians have started the world’s first clinical trial using a new form of stereotactic body radiotherapy (SBRT) to deliver radiation to a specific area of the prostate invaded with cancer – instead of the entire gland. The study aims to determine if treating a targeted cancer region within the prostate in early stage prostate cancer can increase treatment options and reduce the side effects of radiation.
 
If successful, the trial could have a significant impact on the standard of care for men diagnosed with low or intermediate risk prostate cancer.
 
The trial’s first patient was enrolled and underwent therapy earlier this month without any side effects reported to date. The procedure was performed jointly by his urologist, Lee Ponsky, MD, of the UH Urology Institute and a study co-investigator, and his radiation oncologist Rodney Ellis, MD.


Thursday, April 21, 2016

Two Case Western Reserve University faculty members inducted into prestigious medical honor society

CLEVELAND –  Two members of the faculty of Case Western Reserve University School of Medicine, Drs. Derek Abbott and Goutham Narla, have been inducted into the American Society for Clinical Investigation (ASCI), one of the nation’s oldest and most prestigious medical honor societies for physician-scientists. ASCI emphasizes translating findings in the laboratory to the advancement of clinical practice.

Election to the Society reflects a major early-to-mid-career achievement since new members must be 50 years of age or younger. The 2016 Case Western inductees are:

Derek Abbott, MD, PhD, the Arline H. and Curtis F. Garvin Professor of Medicine; Dr. Abbott was elected for his work combining molecular, bioinformatic, and proteomic approaches to identify and pharmaceutically target novel inflammatory signaling pathways. Cell signaling governs basic cellular activities and coordinates cell actions. Disturbance or errors within this communication chain can lead to various diseases and cancers. Better understanding of cell signaling can lead to more effective treatment of diseases.

Goutham Narla, MD, PhD, assistant professor, Case Western Institute for Transformative Molecular Medicine and Pardee-Gerstacker Professor in Cancer Research at the School of Medicine. He also is a University Hospitals Harrington Discovery Institute Distinguished Scholar (early career award), as well as a medical geneticist at UH Case Medical Center, specializing in the care of high risk cancer patients. Dr. Narla was elected for his contributions to an understanding of novel mechanisms of tumor suppressor gene inactivation. His work includes the development of strategies to reactivate tumor suppressor gene function for treating human cancer. 



You must be logged in to view this item.



Login

This area is reserved for members of the news media. If you qualify, please update your user profile and check the box marked "Check here to register as an accredited member of the news media". Please include any notes in the "Supporting information for media credentials" box. We will notify you of your status via e-mail in one business day.